French Biotech Stock News

With no single headline event driving attention today, Dassault Aviation société anonyme (ENXTPA:AM) is drawing interest after a period of strong share price moves. This is prompting investors to reassess how its fundamentals line up with recent returns. See our latest analysis for Dassault Aviation société anonyme. The recent 7.2% 7 day share price return, building on a 10.0% 30 day and 33.0% 90 day share price return, comes on top of a 53.4% 1 year total shareholder return and leaves the...

Lagardere (ENXTPA:MMB) is back in focus after releasing its full year 2025 results. The company reported higher sales, revenue, and earnings per share, along with a record adjusted EBIT and lower net debt. See our latest analysis for Lagardere. The earnings release comes after a period where short term share price momentum has been modest, with a 7 day share price return of 3.82% and a 1 year total shareholder return decline of 8.36%, hinting that the market is still weighing improved...

Context for Euronext’s Recent Share Performance Euronext (ENXTPA:ENX) has drawn fresh attention after recent share price moves, with the stock up 4.8% over the past month but showing a 1.1% decline over the past 3 months. See our latest analysis for Euronext. Looking beyond the recent bounce, Euronext’s share price return over the past year has been more muted than its very large 3 year total shareholder return of about 7x. This suggests that earlier momentum has cooled even as investors who...

Why Nexans is on investors’ radar today Nexans (ENXTPA:NEX) has attracted fresh attention after recent share price moves, with the stock showing mixed short term performance and stronger multi year total returns that may prompt investors to reassess the cable maker’s profile. See our latest analysis for Nexans. Recent trading has been choppy, with a 7 day share price return of an 8.36% decline and a relatively flat 30 day share price return of a 0.39% decline. However, the 1 year total...

Sartorius Stedim Biotech (ENXTPA:DIM) just released its full year 2025 results, reporting sales of €2,967.5m and net income of €265.6m, putting fresh financial data in focus for shareholders. See our latest analysis for Sartorius Stedim Biotech. The latest full year results land at a time when momentum has been mixed, with a 3.86% 1 day share price return and 4.46% 7 day share price return, compared with a 1 year total shareholder return of 10.25% and a 42.86% 3 year total shareholder return...

Schneider Electric (ENXTPA:SU) has introduced EcoStruxure Foxboro Software Defined Automation, an open, software-defined distributed control system designed to tackle aging infrastructure, high operating costs, and modernization needs in hybrid and process industries. See our latest analysis for Schneider Electric. The EcoStruxure Foxboro SDA launch lands at a time when Schneider Electric’s 1 month share price return of 13.65% and 90 day share price return of 17.81% suggest firming momentum...

Wondering if EssilorLuxottica Société anonyme is fairly priced at its current level, or if the market is missing something about its long term potential. The share price closed at €238.20, with returns of 7.8% decline over the past week, 11.1% decline over the past month, and 10.3% decline year to date, while the 1 year return is 16.8% decline, compared with gains of 52.5% over 3 years and 90.7% over 5 years. These mixed return figures suggest that sentiment around the stock has shifted over...

If you are wondering whether Sanofi shares are offering fair value at around €79.58, you are not alone. This article is built to help you weigh what the current price might be saying. Over the past week the stock is up 2.5%, while the 1 year return sits at a 20.2% decline and the year to date return is a 3.3% decline, with a relatively flat 3 year return of 0.2% and a 5 year return of 27.9%. Recent headlines around Sanofi have focused on the broader healthcare and pharmaceuticals space,...

Abivax (ENXTPA:ABVX) presented new preclinical and clinical data for obefazimod at the ECCO Congress. The data highlighted anti fibrotic activity in Crohn's disease and rapid symptomatic relief in inflammatory bowel disease. Large Phase 3 trials were reported to show a strong safety profile and further validation of obefazimod's miR 124 targeting mechanism. Abivax focuses on inflammatory and autoimmune diseases, with obefazimod positioned as its lead asset in inflammatory bowel disease. For...

L'Air Liquide (ENXTPA:AI) drew attention after reporting full year 2025 results, with net income of €3,517.9m on sales of €26,940.2m, alongside a proposed 12.1% higher dividend of €3.70. See our latest analysis for L'Air Liquide. The proposed 12.1% dividend increase and solid full year 2025 net income appear to have fed into recent optimism, with a 1 month share price return of 11.68% at €175.56 and a 5 year total shareholder return of 86.58%. This suggests that momentum has been building...

Tikehau Capital (ENXTPA:TKO) has drawn fresh attention after reporting full year 2025 earnings, with net income of €136.4 million, a proposed €0.80 dividend per share, completed buybacks, and upcoming board changes. See our latest analysis for Tikehau Capital. The strong 1 day share price return of 6.88% to €17.10, alongside a 15.54% 3 month share price return, contrasts with a 1 year total shareholder return of 18.11% decline. This suggests recent momentum has not yet reversed longer term...

Why FDJ United’s latest moves matter for shareholders FDJ United (ENXTPA:FDJU) is back in focus after a packed update, combining full year 2025 results, a proposed dividend increase, fresh 2026 guidance and senior leadership changes on the executive committee. For you as an investor, this mix of operational data, payout policy and management reshuffle helps frame how the business is being run and how shareholder returns are being approached over the coming year. See our latest analysis for...

Without a clear single news catalyst, Danone (ENXTPA:BN) tends to draw attention from investors through its recent share performance, dividend profile, and how its current valuation compares with its underlying fundamentals. See our latest analysis for Danone. At a share price of €73.6, Danone has recently seen a 7.82% 1 month share price return, while its year to date share price return is a 3.21% decline. The 1 year total shareholder return of 10.57% and 3 year total shareholder return of...

Kering (ENXTPA:KER) is back in focus after reporting full year 2025 results that showed sales of €14,675m and net income of €72m, sharply below the prior year’s figures. See our latest analysis for Kering. The weak 2025 earnings, the proposed lower ordinary dividend of €3.00 per share and the leadership change at Bottega Veneta have come against a backdrop of a 6.14% 90 day share price decline and a 44.92% 3 year total shareholder return loss. This signals pressure rather than momentum,...

DBV Technologies (ENXTPA:DBV) is back in focus as it prepares to share fresh VITESSE Phase 3 data on its VIASKIN Peanut Patch at the 2026 AAAAI Annual Meeting, spotlighting peanut allergy treatment in young children. See our latest analysis for DBV Technologies. Those upcoming VITESSE Phase 3 readouts and recent conference appearances come after a sharp shift in sentiment, with the share price at €3.56, a 90 day share price return of 48.95% and a 1 year total shareholder return above 300%,...

If you are wondering whether Nexans is still reasonably priced after its recent run, or if the value story has started to cool, this article is for you. The share price closed at €126.60, with a 9.8% decline over the past week, a 2.2% gain over the last 30 days, and returns of 21.4% over 1 year, 47.9% over 3 years, and 123.2% over 5 years. These moves have put valuation back in focus, especially for investors comparing the recent short term pullback with the stronger multi year returns. With...

Sanofi (ENXTPA:SAN) has wrapped up FY 2025 with fourth quarter revenue of €12.2b and a basic EPS loss of €0.67, alongside trailing 12 month revenue of €46.7b and EPS of €4.05 that still reflect the impact of a large one off €3.4b charge. Over recent periods, revenue has moved between €10.6b and €14.2b a quarter, while basic EPS has ranged from €1.01 to €2.32 in the first three quarters of 2025 before this latest loss. This sets a mixed backdrop for the trailing 10.6% net margin versus 12.4% a...

Verallia Société Anonyme is reviewing its European operations, including potential site closures and job cuts, as part of its sustainability and investment plans. The review focuses on facilities in Germany, France, and the UK, where the company is responding to weaker demand for glass packaging. These possible changes could affect employees and production capacity across key European markets. For investors watching ENXTPA:VRLA, this operational review comes after a period of weaker share...

As European markets navigate volatility with the STOXX Europe 600 Index reaching new highs but ending largely unchanged, investors are closely monitoring the impact of AI disruption concerns and robust U.S. job data on their portfolios. In this climate, dividend stocks can offer a measure of stability and income, making them an attractive option for those seeking to balance growth potential with consistent returns.

Safran SA's ( EPA:SAF ) stock was strong after they recently reported robust earnings. However, we think that...

As European markets navigate volatility amid global concerns about AI disruption and economic data surprises, the STOXX Europe 600 Index recently achieved a new high before settling with a modest gain. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

If you are wondering whether Vinci's current share price still offers value, this article will walk through what the numbers are really saying about the stock. Vinci shares last closed at €137.75, with returns of 3.1% over 7 days, 18.6% over 30 days, 13.7% year to date, 32.2% over 1 year, 42.1% over 3 years, and 88.0% over 5 years, which may influence how you think about the risk and reward trade off today. Recent price moves sit against a backdrop of ongoing interest in large infrastructure...

If you are wondering whether LVMH Moët Hennessy - Louis Vuitton Société Européenne is attractively priced today, it helps to step back from the brand power and look closely at what the current share price actually implies. The stock last closed at €533.90, with a 1.7% gain over the past 7 days, but a 8.4% decline over 30 days, a 16.8% decline year to date, and a 20.9% decline over 1 year, while the 5 year return sits at 9.3% and the 3 year return at a 30.1% decline. Recent coverage around...

Carrefour share move and recent performance snapshot With no single headline event driving recent trading, Carrefour (ENXTPA:CA) has drawn attention after a 4.8% decline over the past day, set against a 5.3% gain over the past month. Over the past 3 months, the stock shows a 14.1% total return, while the past year sits at 16.3%. Year to date, performance is closer to 1.7%. This points to a different picture over shorter periods. See our latest analysis for Carrefour. At a share price of...